The Massachusetts Biotechnology Council's annual industry snapshot, released Monday, contains what looks like a contradiction, and the contradiction is the story. In 2025, the state's biopharma workforce shrank by about 3,600 jobs, or 3.1 percent, to 113,503. It was the first annual decline since at least 2002, the entire period the council has tracked the number. And the same report describes 2026 as the year the sector came roaring back, with venture funding up 25 percent, eight public offerings, eleven acquisitions worth $18 billion, and a biotech stock index up more than a third.
Both halves of the report are true. They are just true at different speeds, and the gap between the speeds is what a headline about a slump and a turnaround keeps missing. Jobs are the slowest number in the industry. Money is the fastest. The 2025 employment decline describes decisions made in 2024 and earlier. The 2026 capital surge describes bets being placed right now. A sector read through its slowest signal will always look like it is still falling when it has already turned.
The report contains two stories in one document
The MassBio release carries both stories in its own title: a "strong resurgence of capital even as workforce numbers lag." The jobs half is genuinely grim. The council attributes the contraction to industry headwinds and to uncertainty about federal funding for scientific research, layered on top of the pandemic-era buildout that left whole lab buildings in Greater Boston empty. The losses were concentrated in Middlesex County, home to Kendall Square, though Boston and Worcester partially offset them. Moderna alone shed nearly a third of its local workforce, from 4,434 employees in 2024 to 3,042 in 2025, a retrenchment the council describes as post-COVID normalization.
The decline was not evenly distributed, and the distribution matters. Research and development positions fell by 2,563, or 3.9 percent, the steepest drop among major U.S. R&D hubs after Maryland and Washington. California, New York, and Florida added R&D jobs. Biomanufacturing, by contrast, grew, adding 238 positions, or 2.4 percent, its second reversal in as many years, with the gains concentrated in advanced-modality work. Total wages still rose 2.2 percent, to $26.45 billion, even as headcount fell. The state that lost the jobs kept 22.3 percent of the nation's entire biopharma R&D workforce.
The composition of the decline is worth pausing on, because it changes what the cluster is becoming. The jobs lost were concentrated in research. The jobs added were in biomanufacturing, 238 of them, with the gains in advanced-modality production. A cluster that sheds R&D positions while adding production positions is not simply smaller. It is different, moving a step downstream, closer to the factories and farther from the benches, and the distinction matters because the research jobs are the cluster's reason to exist in the first place. Manufacturing follows wherever costs and incentives point. The scientists are the agglomeration, and the 2025 numbers show California, New York, and Florida adding the R&D jobs that Massachusetts shed.
Then the report turns the page, and the page looks like a different year. Venture funding reached $3.45 billion in the first half of 2026, up 25 percent from a year earlier and the strongest opening half since 2023. Eight Massachusetts companies went public in the same six months, matching the combined total of 2024 and 2025. Eleven biotechs were acquired for $18 billion, against $7.6 billion at the same point last year, including Biogen's roughly $5.6 billion purchase of Apellis Pharmaceuticals. Eli Lilly more than doubled its Massachusetts workforce, from 540 to 1,423. Sanofi added 385 jobs, AbbVie 326, Alnylam 269. The XBI biotech index is up more than 34 percent for the year and sits near its February 2021 peak.
Capital moves in months; jobs move in years
The two halves are not in conflict. They are the same industry measured on two different clocks. Capital commits quickly. A venture round closes in weeks, an IPO in months, an acquisition in a quarter. Jobs, by contrast, are a lagging indicator by construction. A company that decided to cut its workforce in 2024 or 2025 keeps cutting through the quarters that follow. A company that raises money in March hires in September, and the hiring shows up in next year's snapshot, not this year's. Even the report's own employment figure for 2024, growth of 0.1 percent, was the slowest in the record before the decline arrived. The slowdown was visible in the trend long before the number crossed zero.
This is why the "first decline since 2002" framing deserves care. The phrase makes 2025 sound like a repeat of the last bust, but the comparison year is doing the work. The number fell for the first time since the record began, and it fell by 3.1 percent, which is a real loss, thousands of real jobs. It is also a loss that was already priced into every other indicator in the sector a year before it was reported. The money that fled Massachusetts biotech in 2022 and 2023 returned in 2025 and 2026. The jobs are only now catching up to where the money went, in both directions.
The sequence runs the same way in reverse. The empty labs that symbolized the downturn were commissioned during the boom, when money was abundant and space was scarce. The leases that went bad in 2024 and 2025 were signed in 2021. A slump in biotech is never created in the year it is reported. It is created in the boom, then discovered in the hiring freeze, then counted in the jobs report, and by the time the counting is done the money has already moved on to the next thing.
The fast indicator has its own warning in it
The fast numbers carry their own caution, and it sits exactly where you would not expect a caution to sit: in the earliest money. Average seed rounds declined to $4.65 million in the first half of 2026, from $7.65 million a year earlier, even as later-stage Series A rounds grew. MassBio's chief executive, Kendalle Burlin O'Connell, flagged the same concern from the other side, saying "the lagging workforce numbers still show the scars" and naming as her biggest worry keeping the earliest, riskiest startups and their talent in Massachusetts.
That detail matters because it shows what a leading indicator looks like when it turns skeptical. The capital recovery is real, but it is concentrated in the stages that fund companies with data, not ideas. The newest companies, the ones that will employ the next generation of Massachusetts scientists, are raising smaller rounds. The slowdown that showed up in jobs in 2025 is the same slowdown that is showing up in seed checks now, just moved up the pipeline by a few years. If the seed drought persists, it will arrive in the workforce numbers sometime around 2029, and it will arrive looking like another mystery decline in an otherwise healthy report.
The 2002 comparison does its own quiet work in all of this. The phrase "first decline since at least 2002" invites the memory of the last bust, the genomics crash, the empty buildings after the first biotech bubble. But a 3.1 percent retrenchment after a two-decade run is not a repeat of 2002. It is the normal business of a cyclical industry, and the report's own fast numbers show the cycle already turned. The benchmark makes the decline legible at the price of making it sound like a regression. What the data actually show is a sector that spent 2025 absorbing the boom's hangover while its financiers had already moved on to pricing the next boom.
The sector keeps being read by its slowest number
None of this is a criticism of the snapshot, which measures what it measures accurately and has for two decades. The problem is the habit of reading the whole industry through the one number that moves last. Employment is the number that makes headlines, because jobs are concrete and countable and politically legible. But by the time a job exists in the data, every decision that created it has already been made, funded, and staffed. The jobs number is a photograph of the industry's past, taken in the present, and the industry itself has moved on.
Massachusetts biopharma is not a workforce with some capital attached. It is a capital ecosystem with a workforce attached, and the capital moved first, as it always does. The slump the jobs number recorded in 2025 was over in the money by 2025's own halfway point, if not earlier. The turnaround the capital number is recording now will not fully arrive in the jobs data for another year or two, by which point the next turn, whatever it is, will already be visible somewhere faster.
The honest reading of the report is not "slump, then comeback." It is that the industry has been moving all along, and the measure people watch most closely is the one that moves last. Massachusetts lost biotech jobs for the first time in two decades, and the report that announced the loss is also the report that shows the industry had already started spending again. The jobs will catch up. They always do. What they will catch up to is not the sector the money left in 2022, but the one it is building now, and that is a different story than the one the employment line, left on its own, would tell.
Primary sources
- The MassBio announcement of the 2026 industry snapshot for the employment figures, the R&D and biomanufacturing breakdowns, the wage total, the 2026 venture, IPO, and acquisition figures, the seed-round comparison, and the chief executive's comments.
- The Boston Globe report by Jonathan Saltzman for the framing of the slump, the reporting on empty lab buildings, and the federal funding uncertainty.
- BioSpace's coverage for the comparisons with Maryland, Washington, California, New York, and Florida R&D employment, and Banker & Tradesman for the first-decline-since-2002 framing.